- Home
- LDP vs MGTX Comparison
LDP vs MGTX Comparison
Compare LDP & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- MGTX
- Stock Information
- Founded
- LDP 2012
- MGTX 2015
- Country
- LDP United States
- MGTX United States
- Employees
- LDP N/A
- MGTX N/A
- Industry
- LDP Finance Companies
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDP Finance
- MGTX Health Care
- Exchange
- LDP Nasdaq
- MGTX Nasdaq
- Market Cap
- LDP 619.1M
- MGTX 622.0M
- IPO Year
- LDP N/A
- MGTX N/A
- Fundamental
- Price
- LDP $21.14
- MGTX $8.37
- Analyst Decision
- LDP
- MGTX Strong Buy
- Analyst Count
- LDP 0
- MGTX 2
- Target Price
- LDP N/A
- MGTX $24.00
- AVG Volume (30 Days)
- LDP 102.5K
- MGTX 577.3K
- Earning Date
- LDP 01-01-0001
- MGTX 08-11-2025
- Dividend Yield
- LDP 7.91%
- MGTX N/A
- EPS Growth
- LDP N/A
- MGTX N/A
- EPS
- LDP N/A
- MGTX N/A
- Revenue
- LDP N/A
- MGTX $34,508,000.00
- Revenue This Year
- LDP N/A
- MGTX $228.65
- Revenue Next Year
- LDP N/A
- MGTX $145.06
- P/E Ratio
- LDP N/A
- MGTX N/A
- Revenue Growth
- LDP N/A
- MGTX 203.23
- 52 Week Low
- LDP $16.16
- MGTX $3.85
- 52 Week High
- LDP $20.30
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- LDP 57.13
- MGTX 62.96
- Support Level
- LDP $20.80
- MGTX $8.32
- Resistance Level
- LDP $21.00
- MGTX $8.95
- Average True Range (ATR)
- LDP 0.16
- MGTX 0.40
- MACD
- LDP -0.05
- MGTX -0.07
- Stochastic Oscillator
- LDP 54.67
- MGTX 52.16
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.